Bionaturis and BBD BioPhenix – the two companies that comprise the Bionaturis Group –  have solidified their international scope in the latest edition of the Bio Convention, held this year in Philadelphia and considered an annual landmark in the worldwide biotech sector. During the event, our delegates engaged in significant one-on-one meetings with current and future customers demonstrating the increasing interest in the Group.

Bionaturis Development Area Manager, Dr. Juan Jose Infante; BBD BioPhenix General Manager, Mr. Andoni Cruz; and the Global Sales Manager, Mr. Eli Kehrli, were the Group’s delegates at the most important global biotech event of the year which brings together more than 15,000 biotech companies from 65 different countries.

The main goals of Bionaturis were focused on the consolidation and monitoring of current customers and in establishing new contacts with future customers and partners. In human health, Bionaturis progressed in its collaboration with BMI, a strategic partner in the US, for the joint development and manufacture of a recently validated antiviral vaccine technology on the Groups expression platform, Flylife. In animal health, Bionaturis’ delegates, Dr. Infante and Mr. Kehrli, held bilateral meetings with the business development managers of the largest multinational vet companies that represented both current customers as well as potential future collaborators. During these meetings, they dealt with key issues for the licensing of products currently in Bionaturis’ portfolio.

BIO DELEGATES STAND

According to Dr. Infante, “with a more and more complete portfolio, our potential partners can find in Bionaturis Group a wide variety of possibilities that positions Bionaturis Group as the perfect partner in the development of biological medicines for both human and animal health. Being conscious of the changing requirements of the market, our business model adapts perfectly to the needs of each customer. The quantity and quality of the meetings is a demonstration of our positioning in the development of biopharmaceutical products for animal health”.

According to Eli Kehrli, who recently joined the Bionaturis Group team, “the balance of our activities in the Bio Convention were very positive. Our services are more and more necessary for multinational companies, and the current growth we are experiencing allows us to be more competitive in the marketplace”.

For his part, Andoni Cruz (BBD BioPhenix) commented that “our presence in the Bio Convention each year better positions us in the value chain of the health sector and also in other sectors such as petrochemicals or nutraceuticals”. The BBD BioPhenix division of the company specializes in toxicity and efficacy assays with the zebrafish animal model.  Mr. Cruz also had high-level meetings in which he consolidated already existing collaborations and established new relationships with pharmaceutical multinational companies.  Mr. Cruz stated “Our goal is to reach new agreements and contracts thanks to these meetings held at the Bio 2015”.

Bionaturis Group –through BBD BioPhenix –again had a booth within the space assigned to BioBasque in the Spanish Pavillion.

About Bionaturis Group

The Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccine research, Bionaturis Group closed the 2014 fiscal year with a 73% increase in sales and a positive EBITDA of 29% compared to the previous year. The biotechnological Group which envisions global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).